Article citationsMore>>
Schroth, W., Antoniadou, L., Fritz, P., Schwab, M., Muerdter, T., Zanger, U.M., Simon, W., Eichelbaum, M. and Brauch, H. (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. Journal of Clinical Oncology, 25, 5187-5193. doi:10.1200/JCO.2007.12.2705
has been cited by the following article:
-
TITLE:
More Stable, More Estrogenic: The SERM-ERα LBD Complex
AUTHORS:
Li Gao, Yaoquan Tu, Leif A. Eriksson
KEYWORDS:
Breast Cancer; Tamoxifen Resistance; Molecular Dynamics Simulations;
Dihydrobenzoxathiin; SERM
JOURNAL NAME:
Journal of Biophysical Chemistry,
Vol.2 No.3,
August
9,
2011
ABSTRACT: Many synthetic selective estrogen receptor modulators (SERMs) have been cocrystallized with the human estrogen receptor α ligand binding domain (ERα LBD). Despite stabilizing the same canonical inactive conformation of the LBD, most SERMs display different ligand-dependent pharmacological profiles. We show here that increased partial agonism of SERMs is associated with increased conformational stability of the SERM-LBD complexes, by investigation of dihydrobenzoxathiin-based SERMs using molecular modelling techniques. Analyses of tamoxifen (TAM) and 4-hydroxytamoxifen (OHT) in complex with the LBD furthermore indicates that the conversion of TAM to OHT increases both the affinity to ERα and the partial agonism of the anti-cancer drug, which provides a plausible explanation of the counterintuitive results of TAM therapy.
Related Articles:
-
Melanie von Brandenstein, Julia Straube, Christina-Maria Geisbüsch, Luka Ozretić, Yasemin Ural, Verena Kirn, Wolfram Malter, Jochen W. U. Fries
-
Giancarlo T. Tomezzoli
-
Bambara Augustin Tozoula, Ouedraogo Nina-Astrid, Atenguena Okobalemba Etienne, Kabore Bernard, Akanni Fayçal, Sama Alice Cynthia, Ousseini Diallo
-
Bidyapati Jha, Hari Prasad Lamichhane, GisupNikha Prasiko, Raju Prasad Srivastava
-
Nicola Sarandria